Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifunctional PVP/PEG Hydrogel Coatings Functionalized with Taxifolin for Surface Modification of Titanium-Based Substrates.

International journal of molecular sciences·2026
Same author

Development of Glutathione Hydrogel Carriers Containing Zinc Oxide Microparticles for Skin Regeneration Processes.

International journal of molecular sciences·2025
Same author

Investigating the role of GPR39 in treatment of stress-induced depression and anxiety.

Psychopharmacology·2025
Same author

Repeated Sulforaphane Treatment Reverses Depressive-like Behavior and Exerts Antioxidant Effects in the Olfactory Bulbectomy Model in Mice.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

Synthesis and biological evaluation of novel 3-(5-substituted-1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with a dual affinity for serotonin 5-HT<sub>1A</sub> receptor and SERT.

Bioorganic chemistry·2023
Same author

Chronic memantine disrupts spatial memory and up-regulates Htr1a gene expression in the hippocampus of GPR39 (zinc-sensing receptor) KO male mice.

Brain research·2023

Related Experiment Video

Updated: May 13, 2026

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

GPR39 up-regulation after selective antidepressants.

Katarzyna Młyniec1, Gabriel Nowak

  • 1Department of Biochemical Toxicology, Jagiellonian University Medical College, Medyczna 9, PL 30-688 Kraków, Poland. katarzyna.mlyniec@uj.edu.pl

Neurochemistry International
|March 12, 2013
PubMed
Summary

This study reveals that the GPR39 zinc-sensing receptor is upregulated by certain antidepressants, suggesting its role in their mechanism of action. This finding offers new insights into antidepressant drug development.

More Related Videos

Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization
09:49

Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization

Published on: May 12, 2017

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Related Experiment Videos

Last Updated: May 13, 2026

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization
09:49

Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization

Published on: May 12, 2017

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Zinc plays a role in neural transmission via the GPR39 Zn²⁺-sensing receptor.
  • Preclinical and clinical studies have indicated antidepressant properties of zinc.

Purpose of the Study:

  • To investigate the involvement of the GPR39 receptor in the mechanism of antidepressant action.
  • To measure GPR39 receptor expression in mouse frontal cortex after treatment with various antidepressants.

Main Methods:

  • Mice were treated with imipramine, escitalopram, reboxetine, or bupropion for 14 days.
  • GPR39 receptor protein levels in the frontal cortex were measured using Western Blot analysis.

Main Results:

  • Escitalopram, reboxetine, and bupropion significantly upregulated GPR39 receptor protein levels (by 290%, 816%, and 272%, respectively).
  • Imipramine treatment did not result in significant changes in GPR39 receptor expression.

Conclusions:

  • This study provides the first evidence for the involvement of the GPR39 Zn²⁺-sensing receptor in the antidepressant effects of selective monoamine reuptake inhibitors.
  • The findings suggest that GPR39 may be a novel therapeutic target for antidepressant drug development.